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Do steroid hormones have an important role on cutaneous lupus 
physiopathology?*












An	 80-year-old-Caucasian-woman	 has	 been	
followed during the last 25 years for cutaneous dis-




hydroxychloroquine,	 combined	 intermittently	 with	
intralesional and systemic steroids. Her medical histo-
ry was otherwise not relevant and she had never been 
a smoker.
Four years ago she underwent radical left mas-
tectomy for carcinoma ductal in situ with positive 
oestrogen	 receptors,	 followed	 by	 hormonotherapy	
with	 letrozole	 2,5mg/day.	 A	 month	 later	 there	 was	
pronounced cutaneous worsening and the lesions 
became refractory to previously effective therapies 
(Figure	1).	There	were	no	other	recently	started	medi-
cations or systemic complaints; routine blood labora-
tory tests and autoimmunity antibodies were within 
normal	range.	Acitretin	25mg/day	was	attempted	but	
An Bras Dermatol. 2015;90(5):766-8.
Figure 1: A: Multiple	well-defined	erythematous	plaques	distributed	over	convex	areas	of	the	face;	B:	Marked	inflammatory	infiltration	of	
the	scalp	with	follicular	plugging,	adherent	scale	and	alopecia
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there was further clinical worsening and immunosup-
pressive therapies were contraindicated by the recent 
malignant neoplasia. Thalidomide 50mg/day was 
then	combined	with	previous	therapies,	with	marked	
clinical	improvement	within	two	weeks,	allowing	the	
discontinuation of systemic steroids and hydroxy-
chloroquine	(Figure	2).	Sustained	therapeutic	efficacy	





lupus	 erythematosus	 (SCLE)	 and	 cutaneous	 discoid	
lupus	erythematosus	(CDLE).	The	pathogenesis	is	not	
well	known	–	it	is	believed	to	stem	from	interplay	be-
tween genetic and environmental factors. Ultraviolet 




and cutaneous steroidogenesis has effects on local im-
munologic activity. Oestrogen stimulates the produc-
tion	of	interferon-y,	interleukin	1,	5,	6	and	10,	increas-
es	B-cell	survival,	enhances	antibody	production	and	
contributes to the persistence of autoreactive T-cells in 
SLE patients.2
Additionally,	 epidemiological	 data	 supports	 a	
role for sexual hormones in lupus susceptibility.1	An	esti-
mated three-fold female predominance among patients 
with cutaneous lesions only has been observed.1 The 
female	preponderance	 is	even	higher	 in	SLE	patients,	
occurring most commonly in reproductive-age women 
and being rare in prepubertal age.1 Furthermore,	report-
ed cases of hormonal-induced SLE and anti-oestrogen 
drug-induced	 SCLE,	 namely	 anastrozole	 and	 tamoxi-
fen,	also	suggest	a	role	for	hormonal	imbalance	in	LE	
pathogenesis. 3-5	However,	no	case	of	CDLE	induced	or	
aggravated by such therapies has been reported to date.
Letrozole	is	a	third-generation	aromatase	inhib-
itor indicated for hormone-sensitive breast cancer in 
postmenopausal women. Its anti-oestrogenic effects 
induce	 nearly	 complete	 suppression	 of	 aromatiza-
tion	 in	all	 tissues.	Theoretically,	aromatase	 inhibitors	
should	 be	 beneficial	 in	 lupus	patients,	 once	 they	 re-
duce cutaneous estradiol production which stimulates 
inflammatory	 pathways.	 Conversely,	 in	 our	 patient,	
letrozole	 paradoxically	 aggravated	 the	 disease,	 per-
haps	 due	 to	 iatrogenic	 hormonal	 imbalance,	 which	
points towards a pathogenic role for cutaneous hor-
monal dysregulation in CLE.
Considering	that	both	pathologies	are	not	rare,	
probably more CLE women will undergo anti-oestro-
gen therapy for breast cancer. Whether the cutaneous 
disease will have the same behaviour as in our patient 
remains unknown. Further studies are warranted to 
access the effect of aromatase inhibitors in CLE pa-
tients.q
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